Navigation Links
Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain
Date:5/6/2009

MONTREAL, May 6 /PRNewswire/ - Aegera Therapeutics is pleased to announce the initiation of a Phase 2a, proof-of-concept, clinical trial for AEG33773, a novel, orally bio-available small molecule therapeutic addressing the under-served market of painful diabetic neuropathy.

The Phase 2a study, entitled A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of AEG33773 versus Placebo in Patients with Painful Diabetic Peripheral Neuropathy will evaluate the efficacy, safety and tolerability of three dose levels of AEG33773 in diabetic patients suffering from significant neuropathic pain. This study is underway in Canada and Aegera will soon initiate trial sites in the Unites States, where the IND has recently cleared the FDA regulatory review process, and also in Europe, where the regulatory documents are now under review by the appropriate regulatory authorities.

"We are very excited about this first Phase 2 study for AEG33773 which has demonstrated robust preclinical in vivo data in multiple models of neuropathic and inflammatory pain. Furthermore, AEG33773 could have the potential to treat chronic pain conditions well beyond painful diabetic neuropathy." commented Dr. Jacques Jolivet, M.D., Senior Vice President Clinical Development of Aegera.

"With the successful conclusion of the Phase 1 safety studies for AEG33773 and the initiation of the first Phase 2a trial in diabetic patients suffering from significant neuropathic pain, we are now focused on successfully completing this trial while identifying an appropriate development partner; this will ensure that our novel agent is developed rapidly and effectively for its first indication while exploring additional indications so as to expand this franchise on a global basis." added Dr. Michael J. Berendt, Aegera's President and CEO.

About Aegera Therapeutics Inc. (www.aegera.com'/>"/>

SOURCE AEGERA THERAPEUTICS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
2. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
3. Aegera Therapeutics welcomes two experienced executives to its board of directors
4. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
5. Aegera Therapeutics phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
6. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
7. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
8. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
9. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
10. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
11. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Sept. 23, 2014 News Facts ... India devoted to genome-based research for human health ... is taking a bite out of oral cancer with ... in India with the help of ... DataDirect Networks (DDN). , To fuel its cutting-edge cancer ...
(Date:9/23/2014)... BOSTON, Mass. (PRWEB) September 23, 2014 ... driven by Semantic Web technology, was named in the ... by Gartner, Inc. , The report details key ... category. , According to Gartner analysts Michael Shanler ... help accelerate innovation activities, expose complex relationships with scientific ...
(Date:9/23/2014)... TX (PRWEB) September 23, 2014 Texas ... fertility clinic in South Austin, expanding a Central Texas ... and San Antonio. The satellite office for the region’s ... andrology options to the South Austin, Buda, Kyle and ... effective and affordable fertility treatment directly to individuals and ...
(Date:9/23/2014)... 23, 2014 Healthcare professionals, ... will convene at the Society for Integrative ... held October 26-28 in Houston, Texas to ... practice in individualized integrative cancer care. This ... psychologists, nutritionists, naturopaths, acupuncturists, and other complementary ...
Breaking Biology Technology:National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 2National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 3National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 4National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 5Cambridge Semantics Identified in Gartner’s ‘Hype Cycle for Life Sciences 2014’ Report 2Opening Doors to a Family: Texas Fertility Center Announces Newest Fertility Clinic in South Austin 2Opening Doors to a Family: Texas Fertility Center Announces Newest Fertility Clinic in South Austin 3International Medical Experts to Discuss Latest Integrative Oncology Research and Its Translation to Personalized Clinical Care at 11th International Conference of SIO 2International Medical Experts to Discuss Latest Integrative Oncology Research and Its Translation to Personalized Clinical Care at 11th International Conference of SIO 3
... Feb. 24 Nektar Therapeutics,(Nasdaq: NKTR ... fourth quarter and,year ended December 31, 2008. , ... year for Nektar," said Howard W. Robin,President and ... unique polymer,conjugation chemistry platform, we advanced numerous proprietary ...
... and Play Capability of MyMedicalRecords Pro to ... Technology Experts Expected at HIMSS09LOS ANGELES, Feb. ... Bulletin Board: FVRL), which through its wholly-owned ... consumer-controlled Personal Health Records ("PHRs") ( www.mymedicalrecords.com ...
... Feb. 24 Particle Sciences Inc. today announced the ... from tissue hydration to the passivation of medical device ... series of patent-pending polymers that allow Particle Sciences to ... PS, Director of New Technologies.Particle Sciences has already used ...
Cached Biology Technology:Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 2Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 3Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 4Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 5Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 6Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 7Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 8Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 9MMR Seeks Its Slice of the Billion-Dollar Stimulus Pie 2MMR Seeks Its Slice of the Billion-Dollar Stimulus Pie 3MMR Seeks Its Slice of the Billion-Dollar Stimulus Pie 4MMR Seeks Its Slice of the Billion-Dollar Stimulus Pie 5Particle Sciences Completes Development of First Product Incorporating its Unique Surface Modification System 2
(Date:9/22/2014)... Yale University researchers are studying a potential new ... respiratory disease in which scars develop in the lungs ... microRNA mimic, miR-29, which is delivered to lung tissue ... fibrosis, it reversed fibrosis after several days. , ... EMBO Molecular Medicine . , "The mimic, when ...
(Date:9/22/2014)... New Rochelle, NY, September 22, 2014Cassava, also known as ... high yields in areas of Africa, Asia, and Latin ... With the availability of novel enzymes and processes designed ... then be used to produce sweeteners such as glucose, ... alternative to corn, as described in a Review article ...
(Date:9/22/2014)... manufacture their own "antifreeze" proteins to survive in ... side effect, researchers report: The protein-bound ice crystals ... when temperatures warm. , The finding is ... Academy of Sciences . , "We discovered what ... evolution of antifreeze proteins in Antarctic notothenioid fishes," ...
Breaking Biology News(10 mins):Reversing the effects of pulmonary fibrosis 2Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 2Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 3
... Honeybees can learn to avoid nectar containing natural plant ... scientists at Newcastle University have found. This means that ... such as almond or apple orchards bees struggle to find ... toxic nectar. With honeybee populations already under stress, the Newcastle ...
... NEW YORK CITY (December 20, 2010)The New York Stem ... member of the inaugural class of NYSCF-Robertson Investigators, who was ... the December 27, 2010 Person of the Year Issue. ... School, was lauded for his discovery of an innovative method ...
... environmental factors cause the diversityor numberof species to increase ... suggested that species diversity continues instead of entering into ... in the Caribbean not only supports the original theory ... resources all work together to achieve equilibrium; it builds ...
Cached Biology News:Bee challenged -- toxin-laden nectar poses problems for honeybees 2Time Magazine names Derrick Rossi to 2010 list of 'People Who Mattered' 2Research shows that environmental factors limit species diversity 2
...
... offers the most comprehensive, cost-effective solution ... have incorporated unprecedented quality into both ... includes proven detection chemistries and antibodies ... TechMate protocol. It also includes our ...
... (X/R) Red System consists of concentrated ... and X/R Red Buffer. The X/R ... to produce red staining that may ... , Buffer, 100 mL , Chromogen, ...
Human Cell Line Slides...
Biology Products: